INTCO MEDICAL(SZ:300677) Sou Hu Cai Jing·2026-02-13 12:54Core Viewpoint - The stock of Yingke Medical (300677) has shown a decline in price and mixed financial performance, with a notable increase in net profit but a decrease in revenue in the latest quarter [1][2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 7.425 billion yuan, an increase of 4.6% year-on-year [2]. - The net profit attributable to shareholders reached 924 million yuan, reflecting a significant increase of 34.47% year-on-year [2]. - The net profit excluding non-recurring items was 484 million yuan, which represents a decline of 19.32% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 2.511 billion yuan, down 2.9% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 214 million yuan, showing a remarkable increase of 113.04% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was 84.28 million yuan, down 25.87% year-on-year [2]. - The company's debt ratio stands at 53.79%, with investment income of 183 million yuan and financial expenses of 127 million yuan [2]. - The gross profit margin is reported at 23.7% [2]. Stock Performance and Market Sentiment - As of February 13, 2026, the stock closed at 39.35 yuan, down 1.82%, with a turnover rate of 1.07% and a trading volume of 49,900 hands, amounting to a transaction value of 198 million yuan [1]. - The net outflow of main funds was 938,000 yuan, accounting for 0.47% of the total transaction value, while retail investors saw a net inflow of 2.7368 million yuan, representing 1.38% of the total transaction value [1]. - Over the last 90 days, four institutions have given buy ratings for the stock [3].